Aurobindo Pharma
| Company type | Public |
|---|---|
| NSE: AUROPHARMA BSE: 524804 | |
| Industry | Pharmaceuticals |
| Founded | 1986 |
| Founders | V. Ramprasad Reddy K. Nityananda Reddy |
| Headquarters | Hyderabad, Telangana, India |
| Products | |
| Revenue | ₹31,724 crore (US$3.8 billion) (2025) |
| ₹6,605 crore (US$780 million) (2025) | |
| ₹3,484 crore (US$410 million) (2025) | |
| Total assets | ₹49,748 crore (US$5.9 billion) (2025) |
| Total equity | ₹32,646 crore (US$3.9 billion) (2025) |
Number of employees | 23,000 (2020) |
| Website | www |
| Footnotes / references Financials as of 31 March 2025. | |
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.